[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638595":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":35,"responsibleParty":53,"collaborators":30,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":30,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":30,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":78,"whyStopped":30,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"The Children's Hospital of Zhejiang University School of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ruxolitinib treatment","EXPERIMENTAL","In this single-arm clinical trial, all eligible subjects will receive the same investigational intervention. The study drug is Ruxolitinib Phosphate Cream, 1.5% (w\u002Fw), supplied in 100 g tubes. The dosing regimen consists of applying a thin layer of the cream to all vitiligo lesions twice daily, with approximately 12 hours between applications. Throughout the treatment period, the total application area must not exceed 10% of the Body Surface Area, and the maximum usage is limited to two tubes (totaling 200 g) per month. The entire investigational intervention will last for 24 weeks, unless a subject meets early discontinuation criteria beforehand. It must be emphasized that this drug is for cutaneous use only and is strictly prohibited for application to mucous membranes (e.g., inside the mouth, vagina) or in or around the eyes.",[13],"Drug: Ruxolitinib 1.5% Cream BID",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Ruxolitinib 1.5% Cream BID",[9],[20,21],"Opzelura","ruxolitinib phosphate cream",[23],{"name":24,"affiliation":5,"role":25},"Yunqing Ren, PhD","PRINCIPAL_INVESTIGATOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","0571-86670281",null,"yqren@zju.edu.cn",{"name":33,"role":28,"phone":29,"phoneExt":30,"email":34},"Jipeng Liu, PhD","liujipeng@zju.edu.cn",[36],{"facility":37,"status":30,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Children's Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","310052","China","CN",{"type":44,"coordinates":45},"Point",[46,47],120.16142,30.29365,{"lat":47,"lon":46},[50,52],{"name":51,"role":28,"phone":29,"phoneExt":30,"email":31},"Yunqing Ren",{"name":51,"role":25,"phone":30,"phoneExt":30,"email":30},{"type":54,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100638595","phase-3-efficacy-and-safety-of-ruxolitinib-cream-in-chinese-children-aged-2-11-years-with-non-segmental-vitiligo-100638595",false,"NCT07595939","Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo","Efficacy and Safety of Ruxolitinib Cream in Children Aged 2-11 Years With Non-segmental Vitiligo: A Single-Center, Real-World Study","Inclusion Criteria:\n\n* Children aged 2 to 11 years, regardless of sex.\n* Clinical diagnosis of non-segmental vitiligo, with affected Body Surface Area (BSA) ≥0.1%, T-VASI score ≥0.1, and total depigmented area not exceeding 10% BSA.\n* Legal guardian voluntarily provides signed informed consent and agrees to scheduled follow-ups.\n\nExclusion Criteria:\n\n* Diagnosis of other forms of vitiligo (e.g., segmental vitiligo).\n* Presence of other hypopigmentary or depigmentary disorders that could interfere with efficacy assessment (e.g., pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macular hypomelanosis, nevus depigmentosus, and tinea versicolor).\n* Prior or current use of any treatment for depigmentation.\n* History of failure with any systemic or topical JAK inhibitor therapy for vitiligo or any other inflammatory condition.\n* Known hypersensitivity to the study drug or its excipients.\n* Concurrent participation in another clinical trial.\n* Considered by the investigator to be unsuitable for the study for any other reason.","ALL","2 Years","11 Years",{"count":66,"type":67},20,"ESTIMATED","INTERVENTIONAL",[70],"PHASE3","The goal of this clinical trial is to evaluate the efficacy and safety of Ruxolitinib Phosphate Cream in treating non-segmental vitiligo in children aged 2 to 11 years under real-world conditions. The main question\\[s\\] it aims to answer are:\n\nPrimary Efficacy: What is the improvement rate (e.g., proportion of participants achieving F-VASI75) after 24 weeks of treatment with Ruxolitinib Phosphate Cream in this population? Safety Profile: What is the safety profile of the treatment over 24 weeks, specifically regarding the incidence of Application Site Acne, Application Site Pruritus, and other adverse events?\n\nParticipants will:\n\nApply Ruxolitinib Phosphate Cream topically to vitiligo lesions as prescribed by the investigator.\n\nAttend scheduled clinic visits at Weeks 4, 8, 12, and 24 for efficacy and safety assessments.\n\nUndergo standardized clinical photography and severity scoring of their vitiligo lesions at each visit.\n\nReport any adverse events or skin reactions experienced during the study period to the research team.",[73],"Vitiligo",[75,76,77],"vitiligo","Ruxolitinib","children","NOT_YET_RECRUITING","2026-05-18",{"date":81,"type":82},"2026-05-19","ACTUAL",{"date":84,"type":67},"2026-06-01",{"date":86,"type":67},"2028-12-31",{"name":5,"class":6},1]